64190-53-0

Upstream product

• 64190-52-9 (8S,20S)-de-A,B-20-(hydroxymethyl)pregnan-8-ol 
• 98-88-4 benzoyl chloride 
• 50-14-6 Calciferol 
• 65-85-0 benzoic acid 

Downstream Products

• 66774-71-8 Benzoic acid (1R,3aR,4S,7aR)-7a-methyl-1-((S)-1-methyl-2-oxo-ethyl)-octahydro-inden-4-yl ester 
• 437609-71-7 Benzoic acid (1R,3aR,4S,7aR)-1-((S)-2-hydroxy-1,5-dimethyl-5-triethylsilanyloxy-hex-3-ynyl)-7a-methyl-octahydro-inden-4-yl ester 
• 437609-72-8 Benzoic acid (1R,3aR,4S,7aR)-1-((S)-1,5-dimethyl-2-oxo-5-triethylsilanyloxy-hex-3-ynyl)-7a-methyl-octahydro-inden-4-yl ester 
• 437609-73-9 Benzoic acid (1R,3aR,4S,7aR)-7a-methyl-1-{(S)-1-[5-(1-methyl-1-triethylsilanyloxy-ethyl)-2H-pyrazol-3-yl]-ethyl}-octahydro-inden-4-yl ester 
• 115527-12-3 (20R)-des-A,B-8β-(benzoyloxy)-23,24-dinorcholan-22-al 
• 145354-28-5 (20R)-des-A,B-8β-(benzoyloxy)-23,24-dinorcholane-22-ol 
• 618879-43-9 (20R)-des-A,B-8β-(bzenzoyloxy)-23,24-dinor-22-(tosyloxy)cholane 
• 98830-20-7 25-hydroxydihydrotachysterol₂ 
• 100858-24-0 (22E,24S)-de-A,B-8β-(benzoyloxy)-25-<(methoxymethyl)oxy>ergost-22-ene 
• 100858-26-2 (22E,24S)-de-A,B-25-<(methoxymethyl)oxy>ergost-22-en-8-one 
• 138079-57-9 Benzoic acid (1R,3aR,4S,7aR)-1-((E)-(1R,4S)-5-hydroxy-1,4,5-trimethyl-hex-2-enyl)-7a-methyl-octahydro-inden-4-yl ester 

Relevant academic research and scientific papers

Vitamin D heterocyclic analogues. Part 1: A stereoselective route to CD systems with pyrazole rings in their side chains

Efficient preparation of two vitamin D CD ring system synthons with pyrazole rings in their side chains is based on the formation of the pyrazole ring from an α-acetylenic ketone.

Analogues of the Inhoffen-Lythgoe diol with anti-proliferative activity

The anti-proliferative activity of a series of ester- and amide-linked Inhoffen-Lythgoe side chain analogues is reported. Whereas the Inhoffen-Lythgoe diol was inactive in these studies, a number of aromatic and aliphatic ester-linked side chains demonstr

2-METHYLENE-19,26-NOR-(20S)-1α-HYDROXYVITAMIN D3

Compounds of formula I are provided where X1 and X2 are independently selected from H or hydroxy protecting groups. Such compounds may be used in preparing pharmaceutical compositions and are useful in treating a variety of biologica

2-alkylidene-18,19-dinor-vitamin D compounds

2-alkylidene-18,19-dinor-vitamin D compounds are disclosed as well as pharmaceutical uses for these compounds and methods of synthesizing these compounds. These compounds are characterized by low bone calcium mobilization activity and high intestinal calc

Vitamin D analogs for obesity prevention and treatment

Methods for treating and preventing obesity, inhibiting adipocyte differentiation, inhibiting increased SCD-1 gene transcription, and/or reducing body fat in a subject include administering at least one analog of 1α,25-dihydroxyvitamin D3 or 1α

25-Hydroxydihydrotachysterol2. An innovative synthesis of a key metabolite of dihydrotachysterol2

A new synthesis of 25-hydroxydihydrotachysterol2 is described. The hydroxylated side-chain is constructed stereoselectively using a chiral Wittig reagent. The A-ring synthon is introduced utilising the Wittig-Horner method as developed by Lythgoe et al. The preparation of the metabolite is carried out in 18 steps.